The ophthalmic drugs market is experiencing optimistic market growth as a result of an increase in the global burden of the geriatric population, increasing cases of various eye disorders and
The ophthalmic drugs market is experiencing optimistic market growth as a result of an increase in the global burden of the geriatric population, increasing.
The Aerie Pharma acquisition brings Alcon two commercialized glaucoma products, as well as a pipeline of programs in various stages of development for other eye diseases. Alcon has been an active dealmaker, turning to M&A as a way to bolster its eye products portfolio and pipeline.
IDA Ireland – FDI employment creation plans near 2019 record levels | Irish Building Magazine ie | Ireland s Leading Construction News & Information Portal irishbuildingmagazine.ie - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from irishbuildingmagazine.ie Daily Mail and Mail on Sunday newspapers.
Markets
Needham analyst Serge Belanger maintained a Buy rating on Aerie Pharma (AERI – Research Report) today and set a price target of $26.00. The company’s shares closed last Tuesday at $17.66.
According to TipRanks.com, Belanger is a 4-star analyst with an average return of 8.8% and a 49.5% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical.
Aerie Pharma has an analyst consensus of Strong Buy, with a price target consensus of $27.25, implying a 47.6% upside from current levels. In a report issued on April 15, Oppenheimer also maintained a Buy rating on the stock with a $26.00 price target.